Lisinopril (cas 76547-98-3) inhibits nuclear transcription factor kappa B and augments sensitivity to silymarin in experimental liver fibrosis
-
Add time:07/12/2019 Source:sciencedirect.com
Therapeutic interventions are still limited in the treatment of liver fibrosis even though an incredible number of publications related to silymarin are produced. This is due to the complex molecular pathogenesis. Several studies pointed to the role of renin-angiotensin system (RAS) in hepatic fibrogenesis. Therefore, the present study was designed to examine the effect of the combination of Lisinopril (cas 76547-98-3) (LIS) with silymarin (SIL) on CCl4-induced hepatic fibrosis along with an in-vitro confirmatory experiment. Rats were treated with LIS (1 mg kg−1) and SIL (30 mg kg−1) as a single agent and as combined to LIS (1 mg kg−1). Our results revealed that down-regulation of NFĸBp65 mRNA expression and inhibition of phosphorylation of NFĸBp65 (at Ser536) and NFĸBia were implicated in the anti-fibrotic effect of both LIS and SIL. Consequently lower levels of NFкB-induced TNF-α, TGF-β1, MMP-2, TIMP-1 and VEGF compared to control group. In addition, levels of α-SMA protein expression and hydroxyproline are decreased in association with marked improvement in liver function, oxidative stress markers and histological picture. In addition, LIS augmented the inhibitory effect of SIL on NFĸB pathway at lower dose level. We concluded that LIS, via targeting NFĸB pathway, increases anti-oxidant capacity of liver tissue and exhibits anti-inflammatory, anti-fibrotic and anti-angiogenic activity and augments sensitivity to SIL. Therefore, LIS is a promising candidate for further clinical investigation in the treatment of liver fibrosis.
We also recommend Trading Suppliers and Manufacturers of Lisinopril (cas 76547-98-3). Pls Click Website Link as below: cas 76547-98-3 suppliers
Prev:Randomized Trial of Lisinopril (cas 76547-98-3) Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer
Next:Effect of amlodipine, Lisinopril (cas 76547-98-3) and allopurinol on acetaminophen-induced hepatotoxicity in rats) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- The incidence of all-cause, cardiovascular and respiratory disease admission among 20,252 users of Lisinopril (cas 76547-98-3) vs. perindopril: A cohort study07/19/2019
- Fast and sensitive LC–MS/MS method for the simultaneous determination of Lisinopril (cas 76547-98-3) and hydrochlorothiazide in human plasma07/18/2019
- Development and characterization of sublingual tablet of Lisinopril (cas 76547-98-3)07/17/2019
- Daily Lisinopril (cas 76547-98-3) vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial07/16/2019
- The cough reflex is upregulated by Lisinopril (cas 76547-98-3) microinjected into the caudal nucleus tractus solitarii of the rabbit07/15/2019
- An innovative validated spectrofluorimetric method for determination of Lisinopril (cas 76547-98-3) in presence of hydrochlorothiazide; application to content uniformity testing07/14/2019
- Effect of amlodipine, Lisinopril (cas 76547-98-3) and allopurinol on acetaminophen-induced hepatotoxicity in rats07/13/2019
- Randomized Trial of Lisinopril (cas 76547-98-3) Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer07/11/2019